Samsung Bioepis collaborates with Teva to launch Epysylli in U.S. market Samsung Bioepis and Teva join forces to introduce a ...

South Korean biosimilars developer Samsung Bioepis and Israel’s Teva Pharmaceutical Industries have entered into a license, ...

Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...

This complaint was first surfaced by Law.com Radar, ALM's source for immediate alerting on just-filed cases in state and federal courts. Law.com Radar now offers state court coverage nationwide. Sign ...

Pharmaceutical Industries announced that the companies have entered into a license, development and commercialization agreement for EPYSQLI, Samsung Bioepis’ biosimilar to Soliris in the United States ...

For more information, or to register for this event, visit The New Era of CDx in Oncology: Adapting Clinical Research Strategy to Evolving Regulations.

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical ...

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH),atypical hemolytic uremic syndrome (aHUS)andgeneralized myasthenia gravis (gMG)in the U ...

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...

Korean firms seek US FDA approval for new anticancer drugs and biosimilars Korean pharmaceutical companies renewed their ...

european qualifiers As the epidemic recedes, new changes in public hospitals begin I-Mab—License-in+independent R&D innovation model shows initial results R&D Daily丨Samsung Bioepis' bevacizumab ...